New Products

Premium

Intrinsic Bioprobes this week launched three assays for protein biomarkers tied to kidney disease and renal failure.

The assays, which are based on the company's Mass Spectrometric Immunoassay technology, quantitate levels of beta-2-microglobulin, cystatin C, and retinol binding protein, which, the company said, are FDA-approved clinical markers for kidney disease and renal failure.

The assays will be offered out of the CLIA-certified diagnostic laboratory of the Institute for Genomics Medicine at the University of Medicine and Dentistry of New Jersey.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.